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The abnormalities of lipid metabolism observed in cancer cachexia may be induced by a lipid-mobilizing factor produced by
adenocarcinomas. The speciﬁc molecules and metabolic pathways that mediate the actions of lipid-mobilizing factor are not
known. The mitochondrial uncoupling proteins-1, -2 and -3 are suggested to play essential roles in energy dissipation and
disposal of excess lipid. Here, we studied the effects of lipid-mobilizing factor on the expression of uncoupling proteins-1, -2
and -3 in normal mice. Lipid-mobilizing factor isolated from the urine of cancer patients was injected intravenously into mice
over a 52-h period, while vehicle was similarly given to controls. Lipid-mobilizing factor caused signiﬁcant reductions in body
weight (710%, P=0.03) and fat mass (720%, P50.01) accompanied by a marked decrease in plasma leptin (759%,
P50.01) and heavy lipid deposition in the liver. In brown adipose tissue, uncoupling protein-1 mRNA levels were elevated in
lipid-mobilizing factor-treated mice (+96%, P50.01), as were uncoupling proteins-2 and -3 (+57% and +37%, both P50.05).
Lipid-mobilizing factor increased uncoupling protein-2 mRNA in both skeletal muscle (+146%, P50.05) and liver (+142%,
P=0.03). The protein levels of uncoupling protein-1 in brown adipose tissue and uncoupling protein-2 in liver were also
increased with lipid-mobilizing factor administration (+49% and +67%, both P=0.02). Upregulation by lipid-mobilizing factor of
uncoupling proteins-1, -2 and -3 in brown adipose tissue, and of uncoupling protein-2 in skeletal muscle and liver, suggests that
these uncoupling proteins may serve to utilize excess lipid mobilized during fat catabolism in cancer cachexia.
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Body fat depletion due to enhanced lipid mobilization is a major
component of weight loss in cachectic cancer patients (Shaw and
Wolfe, 1987; Puccio and Nathanson, 1997). Cachexia can occur
with a small tumour burden, suggesting that tumour-derived
factors catabolize body fat, but their nature and mode of action
have remained elusive.
One putative mediator is a lipid-mobilizing factor (LMF), a 43-
kD protein with homology to Zn-a2-glycoprotein, which was ﬁrst
isolated from the murine MAC16 adenocarcinoma and subse-
quently from the urine of cachectic patients with gastrointestinal
and pancreatic cancers (Todorov et al, 1998). Administration of
human LMF to normal mice over 3 days causes a massive (40%)
reductions in body weight and fat, without changes in muscle mass
or in food or water intake (Hirai et al, 1998). LMF enhances lipo-
lysis in adipocytes and increases serum free fatty acid (FFA) levels,
by activating hormone-sensitive lipase (HSL) through increased
intracellular cyclic AMP levels (Hirai et al, 1998). Notably, LMF
is also implicated in human cancer cachexia, as it is found only
in patients with gastrointestinal tumours that are complicated by
weight loss (Groundwater et al, 1999).
The fate of the FFA and glycerol liberated from lipolysis induced by
LMF is not known. These products must be catabolized and/or
resynthesized in other sites to form triglyceride. Evidence is emerging
that the uncoupling proteins (UCP-1, -2 and -3), members of the
mitochondrial carrier family, may provide mechanisms for disposing
of excess FFA (Samec et al, 1998a; Ricquier and Bouillaud, 2000).
UCP-1 is expressed exclusively in brown adipose tissue (BAT), a
major heat-producing tissue in rodents and human neonates, where
it dissipates the proton electrochemical gradient across the inner
mitochondrial membrane; this uncoupling increases heat production
instead of generating ATP from the oxidation of FFA (Ricquier and
Bouillaud, 2000). UCP-1 expression is stimulated by the sympathetic
nervous system via b3 adrenoceptors, being induced by cold exposure
and b3 adrenoceptor agonists, but falls on fasting (Champigny and
Ricquier, 1990; Bing et al, 1997, 1998). UCP-2 and -3 are two
newly-described homologues of UCP-1. UCP-2 is widely expressed
in most tissues including adipose tissue, muscle, heart and liver
(Fleury et al, 1997), while UCP-3 mRNA is preferentially expressed
in skeletal muscle and BAT (Boss et al, 1997b). Overexpression of
UCP-2 and -3 reduces the mitochondrial membrane potential in
yeast, consistent with uncoupling activity (Fleury et al, 1997; Gimeno
et al, 1997); they are therefore candidate thermogenic mediators in
tissues that lack UCP-1. There is some indirect evidence that they
are involved in heat production in vivo: adipose tissue UCP-2 mRNA
levels correlate with resting metabolic rate in obese women (Barbe et
al, 1998), while transgenic overexpression of UCP-3 in skeletal
muscle of mice stimulates thermogenesis and markedly reduces body
weight and fat (Clapham et al, 2000).
Paradoxically, however, muscle UCP-2 and -3 expression is
increased during fasting when energy expenditure falls (Weigle et
al,1998), raising the possibility thatUCP-2 and-3 serve other physio-
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lipid (especially FFA) metabolism, as various situations that raise
circulating levels of FFA increase both UCP-2 and -3 expression in
white fat and skeletal muscle (Boss et al, 2000). These conditions
include fasting, high-fat feeding and intralipid infusion in rodents
(Boss et al, 1997a; Fleury et al, 1997; Matsuda et al, 1997; Weigle et
al, 1998) and obesity, type-2 diabetes and intralipid infusion in
man (Millet et al, 1997; Bao et al, 1999; Khalfallah et al, 2000; Nisoli
et al, 2000). Moreover, in vitro, FFA up-regulate UCP-2 in pre-adipo-
cytes and hepatocytes, and UCP-3 in muscle cells (Samec et al, 1998b;
Cortez-Pinto et al, 1999; Reilly and Thompson, 2000). Conversely,
inhibition of mitochondrial b-oxidation of fatty acids prevents upre-
gulation of UCP-2 and -3 during fasting in the soleus muscle in rats
(Hwang and Lane, 1999).
These observations suggest that UCP-2 and -3 help to utilize
and dispose of excess lipid. They are therefore strong candidates
for removing lipolytic products generated by LMF in cancer
cachexia. This hypothesis is supported by our recent ﬁndings of
increased expression of UCP-1 in BAT, and of UCP-2 and -3 in
skeletal muscle in mice bearing the MAC16-tumour, which
produces LMF (Bing et al, 2000). However, it is not known
whether UCP expression is induced by LMF or by other MAC16
tumour products, which include a proteolysis-inducing factor
(PIF). This study aimed to verify whether administration of LMF
stimulates expression of UCP-1, -2 and -3 in normal mice.
MATERIALS AND METHODS
Animals
Male NMRI mice (30–35 g) from the inbred colony at Aston
University were housed at an ambient temperature of 22+28C
under a 12:12 h light–dark cycle (lights on at 0700 h) and fed
on standard chow (SDS economy breeder; Lillico, Wonham Mill,
Bletchworth, Surrey, UK), with tap water ad libitum. Food intake
and body weight were monitored daily. All studies were conducted
according to the UKCCCR Guidelines for the care and use of
laboratory animals.
LMF puriﬁcation
LMF was puriﬁed from the urine of cachectic cancer patients who had
suffered 410% weight loss, and was kindly provided by Professor K
Fearon, Department of Surgery, Edinburgh Royal Inﬁrmary, Scot-
land. Urine was diluted with four parts of 10 mM Tris HCl
(pH 8.0) before addition of DEAE cellulose (Whatman International
Ltd, Kent, UK) 2g per litre of diluted urine, previously equilibrated in
100 mM Tris HCl (pH 8.0) for 5 min and then in 10 mM Tris HCl
(pH 8.0) for 5 min, with stirring for 2 h at 48C. The DEAE cellulose
was recovered by low-speed centrifugation (4500 r.p.m. for 3 min)
and LMF was eluted by resuspension (twice) in 0.3 M NaCl in
10 mM Tris HCl (pH 8.0). The eluate was equilibrated and concen-
trated to 1 ml by ultraﬁltration against phosphate-buffered saline
(PBS) in an Amicon ﬁltration cell containing a membrane ﬁlter with
a molecular weight cut-off of 10 kDa. Further puriﬁcation was
achieved using a Resource-Iso HPLC column (Pharmacia Biotech,
St Albans, Herts., UK), employing a decreasing (NH4)2SO4 concen-
tration from 1.5 M. Active fractions containing LMF eluted at 0.6 M
(NH4)2SO4 and were desalted before use by washing ﬁve times
against PBS using an Amicon ﬁltration cell. Biological activity was
determined by glycerol release from mouse epididymal adipocytes,
as previously described (Hirai et al, 1998). The LMF was puriﬁed
to a single band of Mr 43 kDa (Figure 1).
LMF treatment
Repeated intravenous injections of LMF (8 mg) were given to one
group of mice (n=6), while the weight-matched controls (n=6)
were similarly injected with PBS at the same time-points: 0, 7,
11, 24, 32 and 48 h. Food intake and body weight were moni-
tored before each injection, and core temperature was recorded
at 52 h before the mice were killed by cervical dislocaton. Blood
was removed by cardiac puncture and plasma was separated
and stored at 7408C until assay. The interscapular BAT, gonadal
fat pads, gastrocnemius muscle and liver were dissected, snap-
frozen in liquid nitrogen and stored at 7808C until extraction
of RNA.
Liver histology
Liver was sectioned using a cryostat. Five-mm frozen sections were
stained with haematoxylin and eosin, and compared with other
sections stained with Oil Red O to demonstrate triglyceride deposi-
tion. Sections were rinsed in water, and then 60% isopropyl
alcohol, and stained with 1% Oil Red O for 10 min; sections were
then rinsed brieﬂy again as above, and counterstained with Harris
haematoxylin for 1 min. Finally, sections were washed in water,
then mounted in Aquamount (BDH, Leicester, UK).
Immunohistochemistry for caspase 3
This was performed to determine the extent of apoptosis in liver.
Five-mm cryostat sections were ﬁrst ﬁxed on glass slides with 4%
(w v
71) paraformaldehyde. Slides were rinsed three times in PBS,
exposed to 5 mgm l
71 of rabbit anti-caspase 3 (R&D Systems,
Abingdon, Oxfordshire, UK) and incubated at room temperature
for 1 h. After three further rinses in PBS, biotin-labelled anti-
rabbit IgG was applied to the slides for 30 min. Slides were rinsed
in PBS and incubated with horseradish peroxidase-conjugated
avidin (Amersham Pharmacia Biotech; Little Chalfont, Buckin-
ghamshire, UK) for 30 min, and stained with 3,3'-
diaminobenzidine for 5 min. Sections were counterstained with
Mayer’s haematoxylin for 2 min, dehydrated and mounted with
Aquamount.
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Figure 1 Twelve per cent SDS polyacrylamide gel electrophoresis of
human LMF. Lane 1, molecular weight markers; Lane 2, human LMF puriﬁed
from the urine of cachectic cancer patients, showing expected molecular
weight of 43 kDa. Detection was by Coomassie Blue staining.
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Plasma leptin concentrations were measured using a mouse leptin
ELISA kit (Crystal Chemicals, Chicago, USA). Plasma glucose was
measured using a glucose oxidase-based kit (Sigma; Poole, Dorset,
UK), and plasma glycerol and free fatty acids were determined
using enzymatic colorimetric assay kits, respectively from Sigma
and Wako Chemicals (Neuss, Germany). Skeletal muscle and liver
triglyceride concentrations were measured with a kit (Sigma). The
tissue (50 mg) was homogenized in 500 ml PBS with 0.1% BSA and
then centrifuged for 5 min at 2000 g; triglyceride assay was
performed on the supernatant.
Northern blotting
Total RNA was extracted from BAT and gastrocnemius muscle
using Tri-reagent (Sigma) and the RNA concentration determined
from the absorbance at 260 nm. Aliquots of 20 mg were size-frac-
tionated on a 1% agarose-formaldehyde gel, blotted on to a
positively-charged membrane (Boehringer Mannheim, Lewes,
Sussex, UK) and then cross-linked under UV light. UCP-1, -2
and -3 mRNA were detected by Northern blotting in conjunction
with the chemiluminescence method. The membranes were pre-
hybridized in Easyhyb solution (Boehringer Mannheim) at 428C
for 1 h and hybridized in the same solution with a digoxigenin-
labelled 32-mer antisense oligonucleotide probe for mouse UCP-1
(Trayhurn and Duncan, 1994), or digoxigenin-labelled 30-mer
oligonucleotide probes for mouse UCP-2 and -3 (Bing et al,
2000). Each blot was stripped and re-probed for 18S rRNA with
a 31-mer digoxigenin-labelled oligonucleotide, as previously
described (Trayhurn et al, 1995). Autoradiographs were quantitated
by densitometry with image-analysis (AIS System, Imaging Tech-
nology, Brock University, St Catharine’s, Ontario, Canada). The
abundance of mRNA was expressed as the ratio of UCP mRNA/
18S rRNA signals.
Quantitative RT–PCR
Since the signal was too low to be detected by Nothern blotting,
liver UCP-2 mRNA was quantitated using RT–PCR based on a
previously described method (Taylor et al, 1998). Total RNA was
isolated from frozen liver as described above. The primer pairs
for UCP-2 were 5'-TAGCAGGAAATCAGAATCAT-3' and 5'-AA-
GTGGCAAGGGAGGTCATC-3' (Genebank: U69135), which gener-
ated a 668-bp product. The primers for creating UCP-2 competitor
RNA were 5'- AATTTAATACGACTCACTATAGGGATAGCAG-
GAAATCAGAATCAT-3' and 5'-CTCGTGCAATGGTCTTGTAG-3'
in an RT–PCR to produce a DNA fragment containing a 128-bp
deletion and having an additional 25 bases that correspond to a
T7 RNA polymerase-recognition sequence at its 5' end. Competitor
RNA was produced using a T7 RNA polymerase kit (Boehringer-
Mannheim) and quantitated using optical density at 260 nm. Six
serial two-fold dilutions were prepared containing known concen-
trations of the competitor for subsequent RT–PCR.
For cDNA template synthesis, 0.5 mg of total RNA and one of
the dilutions of competitor RNA in a total volume of 27 ml 0.1%
(w v
71) diethylpyrocarbonate (DEPC) water was incubated at
658C for 10 min, then chilled on ice for 2 min. The RNA solution,
together with 0.5 mg oligo dT primer and DEPC water, was added
to the reaction tube with First-Strand Beads (Pharmacia Biotech,
St. Albans, UK) which contained 50 mM Tris (pH 8.3), 75 mM
KCl, 7.5 mM DTT, 10 mM MgCl2, 0.08 mg ml
71 BSA and
2.4 mM each of dATP, dCTP, dGTP and dTTP, and murine reverse
transcriptase in a ﬁnal volume of 33 ml. The contents of the tube
were mixed and incubated at 378C for 1 h.
PCR was performed on a thermal cycler (Hybaid, Ashford, UK),
using 2 ml of template cDNA and PCR reaction mixture (Pharma-
cia Biotech) which gives ﬁnal concentrations of 1.5 units of Taq
polymerase, 10 mM Tris-HCl (pH 9.0), 50 mM KCl, 1.5 mM
MgCl2, 200 mM of each dNTP and 20 pM of each primer in a ﬁnal
volume of 25 ml. Co-ampliﬁcation of UCP-2 and the competitor
was initiated by one cycle of DNA denaturation for 4 min at
948C, followed by 35 cycles of denaturing for 1 min at 948C,
annealing at 57.58C for 1 min and extension for 1 min at 728C.
Finally, an extension for 10 min at 728C was performed.
Control reactions containing all components except RNA or
RNA only were carried out to show that the RNA (both competitor
and target) had no DNA contamination. The target and competitor
PCR products were sequenced in both orientations and contained
the expected sequences and experimentally constructed deletions.
For analysis of results, 10 ml of PCR products were separated in
a 1.5% (w v
71) agarose gel containing ethidium bromide. The gel
images were recorded using a computerized digital camera under
UV transillumination and the intensity of bands analyzed using
1D image analysis software (Kodak Digital Science, Eastman Kodak
Company, Rochester, NY, USA). The ratio of intensity (competi-
tor/target) was plotted against the six known dilutions of
competitor for each sample. The amount of sample RNA corre-
sponds to the amount of competitor when the ratio of
competitor to target is 1.0.
Western blotting
Increases in mRNA of UCPs have been reported under some
conditions in the absence of rises in the respective UCP protein
levels (Sivitz et al, 1999). We therefore used Western blotting to
measure UCP-1 and -2 concentrations. UCP-3 could not be
measured because a suitable antibody is not available. Mitochon-
dria were isolated from BAT and liver of mouse. Samples
containing 30 mg mitochondrial protein were mixed with equal
volumes of 26 SDS loading buffer, incubated at 908C for 5 min,
and separated by electrophoresis on 12% SDS-polyacrylamide gels.
Proteins were then transferred to nitrocellulose membranes
(Hybond C, Amersham Inc, Bucks, UK) and immunological detec-
tion was performed using a rabbit afﬁnity-pure UCP-1 antiserum
(Autogenbioclear, Wilts, UK) at a 1:1000-fold dilution, or a rabbit
afﬁnity-pure UCP-2 antiserum (Calbiochem, San Diego, CA, USA)
at a 1:1000-fold dilution. Blots were then incubated with a goat
anti-rabbit secondary antibody conjugated to horseradish peroxi-
dase (DAKO A/S, Glostrop, Denmark). Detection was by using
enhanced chemiluminescence (ECL; Amersham Inc, Bucks, UK).
The sizes of the proteins detected were estimated using protein
rainbow molecular-mass standards (Amersham Inc, Bucks, UK).
Autoradiographs and ECL signals were quantitated by scanning
densitometry.
Statistical analyses
Data are expressed as mean+s.e.m. Differences between LMF-
treated and control groups were analyzed by the unpaired Student’s
t-test using ARCUS statistical software (Medical Computing, Augh-
ton, UK). Differences were considered as signiﬁcant if P50.05.
RESULTS
LMF reduces body weight and fat mass
Body weight, composition and metabolic data are shown in Table
1. As illustrated in Figure 2, LMF injection caused rapid weight
loss, reaching 10% (P=0.03) below controls at 52 h. Speciﬁcally,
LMF-treated mice showed signiﬁcant reductions in both gonadal
fat mass (20%, P50.01) and interscapular BAT (23%, P50.01),
whereas skeletal muscle mass was unchanged. Food and water
consumption were not signiﬁcantly altered. Core temperature 4 h
after the last LMF injection was slightly higher (+0.6+0.28C) in
LMF-treated mice, but this rise fell short of statistical signiﬁcance.
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British Journal of Cancer (2002) 86(4), 612–618 ã 2002 Cancer Research UKLMF decreases plasma leptin in proportion to reduction of
fat mass
As leptin secreted from adipose tissue regulates body adiposity, we
therefore tested the lipolytic effects of LMF on leptin. Plasma leptin
levels were signiﬁcantly decreased by 59% below controls in LMF-
treated mice (P50.01; Table 1) and this reduction was in propor-
tion to the loss of body fat:plasma leptin was positively correlated
with gonadal fat mass across both control and experimental groups
(r=0.83, P50.01).
LMF upregulates UCP-1, -2 and -3 mRNA
In BAT, LMF treatment signiﬁcantly increased mRNA levels of UCP-
1 (+96%, P50.01), -2 (+57%, P=0.02) and -3 (+37%, P50.05). LMF
also stimulated UCP-2 expression in muscle (+146%, P50.05);
muscle UCP-3 was also increased (+110%), but this rise failed to
reach statistical signiﬁcance (P=0.18) (Figure 3). Liver UCP-2 mRNA
and its competitor mRNA were detectable and quantiﬁed by RT–
PCR (Figure 4A). There was a signiﬁcant increase in liver UCP-2
mRNA expression in LMF-treated mice compared with vehicle-trea-
ted controls (+142%, P=0.03; Figure 4B).
LMF increases protein levels of UCP-1 in BAT and UCP-2
in liver
Using Western blotting, UCP-1 protein levels in BAT were signiﬁ-
cantly increased in LMF-treated mice compared with controls
(+49%, P=0.02; Figure 5), while UCP-2 protein in liver mitochon-
drial preparations were also elevated (+67%, P=0.02; Figure 6).
LMF causes lipid deposition in the liver
Haematoxylin and eosin staining of liver sections from LMF-trea-
ted mice showed no obvious signs of inﬂammation or other
abnormality. However, Oil Red O staining showed abundant intro-
cytoplasmic microdroplets of lipid deposited in hepatocytes in all
zones of the hepatic lobule (Figure 7A). By contrast, hepatocytes
of control mice contained only sparse and small droplets of lipid
(Figure 7B). Caspase 3 immunostaining was no denser or more
extensive in the liver of LMF-treated mice than in controls, indicat-
ing that apoptosis was not enhanced.
DISCUSSION
This study conﬁrms the potent lipolytic effects of LMF in normal
mice, with marked depletion of body fat but no loss of muscle
mass. As well as causing massive adipose tissue catabolism, LMF
must somehow act to prevent the resynthesis of triglycerides in this
tissue. There is evidence of increased lipid utilization following
LMF treatment, including elevation in plasma 3-hydroxybutyrate
concentrations and in oxygen uptake by BAT (Hirai et al, 1998),
but the possibility that other pathways may facilitate LMF-induced
fat catabolism in other tissues has not been explored. Here, we
investigated the possible involvement of UCP-1, -2 and -3.
We found that LMF administration stimulates UCP-1 mRNA
expression in BAT, suggesting that it is at least partly responsible
for the UCP-1 upregulation observed in MAC16-bearing mice
(Bing et al, 2000). The elevation of UCP-1 gene expression also
leads to an increase in the relative abundance of UCP-1 protein
in the BAT mitochondria. These observations are consistent with
the ﬁnding that LMF treatment enhances oxygen consumption by
BAT, suggesting an increase in BAT thermogenesis. The stimula-
tory effects of LMF on UCP-1 expression (and on UCP-2 and -3
in other tissues) could be direct and/or indirect actions of LMF.
The uncoupling mechanism in BAT mitochondria is controlled
by sympathetic afferents via b3-adrenoceptors located on the brown
adipocytes (Ricquier and Bouillaud, 2000); intriguingly, a recent in
vitro study has suggested that the lipolytic effect of LMF is
mediated through the b3-adrenoceptor (Russell et al, 2000). Thus,
it is possible that LMF upregulates expression of BAT UCP-1
directly via b3 receptors. On the other hand, it has been proposed
that uncoupling of BAT mitochondria is activated by FFA which
stimulate UCP-1 as well as serving as a substrate for oxidation
(Trayhurn, 1993; Boss et al, 2000). Addition of FFA to isolated
brown adipocytes mimics the stimulatory effects of catecholamines
on respiration (Prusiner et al, 1968), while stimulatory effects of
both norepinephrine and FFA are absent in brown adipocytes from
UCP-1-ablated mice (Nedergaard et al, 1999). As yet, direct actions
of LMF on UCP expression in these tissues in vitro has not been
investigated.
We also found that LMF administration induced UCP-2 gene
expression in skeletal muscle, brown fat and liver, and UCP-3 expres-
sion in BAT. UCP-2 and -3 are implicated in the regulation of lipids
as a fuel substrate in adipose tissue and skeletal muscle in rodents as
well as in humans (Samec et al, 1998a; Khalfallah et al, 2000; Nisoli et
al, 2000); accordingly, our ﬁndings support a role for UCP-2 and -3
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Table 1 Effects of human LMF on body weight, fat mass, muscle mass
and serum metabolite and leptin levels on NMRI mice 52h after the ﬁrst
injection
a
Control Treated P
Total food intake (g) 7.4+0.9 7.0+0.4 NS
b
Total water intake (ml) 9.4+3.6 10.8+1.6 NS
Final body weight (g) 37.6+1.1 33.7+1.2 0.03
Body weight change (g) 70.06+0.5 72.24+0.2 0.01
Gonadal fat mass (g) 0.76+0.02 0.61+0.04 0.01
Brown fat mass (mg) 91.2+7.7 70.0+5.6 0.05
Gastrocnemius muscle (g) 0.37+0.06 0.35+0.04 NS
Core temperature (8C) 37.6+0.8 38.2+0.5 NS
Liver weight (g) 1.18+0.05 1.34+0.03 0.03
Glycerol (mM) 0.15+0.03 0.09+0.03 0.05
FFA (mmol ml
71) 0.46+0.02 0.49+0.02 NS
Glucose (mmol l
71) 11.6+0.4 6.7+1.0 0.01
Leptin (ng ml
71) 7.0+0.7 2.9+0.6 0.01
Muscle triglyceride (mg dl
71) 8.6+1.3 3.3+0.4 0.01
Liver triglyceride (mg dl
71) 6.5+1.5 14.2+2.8 0.05
aDate are mean+s.e.m. for six mice each group. Differences from control values
were analyzed by Student’s t-test.
bNS=not statistically signiﬁcant.
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Figure 2 Body weight changes in LMF-treated and vehicle-treated con-
trol mice. Arrows indicate time-point of LMF injection. *P50.01; LMF vs
controls. Data are mean+s.e.m. for six mice per group.
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LMF administration also caused massive lipid deposition in the liver
that was associated both with induction of UCP-2 mRNA and mild
increased UCP-2 protein abundance in that organ. UCP-2 has
recently been implicated in hepatic lipid utilization, as exposure to
intralipid emulsions leads to increases in UCP-2 mRNA and UCP-
2 protein levels in cultured hepatocytes (Cortez-Pinto et al, 1999).
Lipid oxidation is known to generate intracellular reactive oxygen
species (ROS) that can cause cell death, while the uncoupling of
respiration can be a powerful mechanism that limits ROS formation.
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Figure 3 Effect of LMF treatment on mRNA levels of UCP-1, -2 and -3 in BAT, and of UCP-2 and -3 in skeletal muscle. Mice were injected with LMF and
tissues were removed at 52 h; control mice received vehicle injections. Total RNA was extracted from mouse BAT or skeletal muscle, and the mRNA levels
of the UCPs were measured using Northern blotting with chemiluminescence detection. Data are mean+s.e.m. for six mice per group, expressed as per-
centage of controls (mean=100%).
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and 3.13 pg. The band density ratios between the target and competitor were determined after photographing the agarose gel and plotted vs the initial
amount of competitor added in the RT–PCR reaction. At the equivalence point (ratio=1), the initial amount of target RNA corresponds to the initial
amount of competitor. (B) Effect of LMF treatment on UCP-2 mRNA in liver. Mice were injected with LMF and liver was removed at 52 h; control mice
received vehicle injections. Data are mean+s.e.m. for six mice per group.
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lates ROS production, while both the ROS-inducing agent tert-
butyl hydroperoxide (TBHP) and tumour necrosis factor-a (TNF-
a) can induce hepatocyte UCP-2 mRNA; this suggests that UCPs
may also serve as an antioxidant defence mechanism (Negre-Salvayre
et al, 1997; Cortez-Pinto et al, 1999; Lee et al, 1999; Arsenijevic et al,
2000). Perhaps consistent with this is the observation that fatty livers
from ob/ob mice or ethanol-fed lean mice show up-regulation of
hepatic transcripts for UCP-2, while hepatocyte death is not increased
(Rashid et al, 1999). In the present study, induction of UCP-2 in liver
when there is an excessive lipid accumulation caused by LMF could
also limit ROS production, thereby preventing cell death. Indeed,
we found no evidence of excess apoptosis in the fatty liver of mice
treated with LMF.
Taken together, our ﬁndings suggest that uncoupling proteins
play a permissive role in enhanced lipolysis in cancer cachexia.
Induction of UCP-1, -2 and -3 expression by tumour-derived
LMF probably provides a mechanism for excessive lipid disposal,
which in turn facilitates the fat catabolic cascade in malignancy.
UCP induction may help to protect these tissues against the oxida-
tive damage that would result from enhanced FFA oxidation.
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Figure 5 (A) Western blot showing UCP-1 concentrations in mitochon-
drial preparations of brown adipose tissue from vehicle-treated and LMF-
treated mice. (B) UCP-1 protein content in control and LMF-treated mice
(mean+s.e.m. of the signals shown in A).
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Figure 6 (A) Western blot showing UCP-2 content in mitochondrial
preparations of liver from vehicle-treated and LMF-treated mice (format
as in Figure 5).
A
B
Figure 7 Histology of mouse liver. Fresh frozen tissue from ﬁve mice per
group was sectioned on a cryostat and stained with Oil Red O. There was
marked intracytoplasmic lipid accumulation in the liver from LMF-treated
mice (B) but little in the vehicle-treated mice (A). Hepatocytes from all
zones of the hepatic lobule were affected equally.
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